Make Informed Investment Decisions with Affordable Access to Experts
Discussing the unmet medical need and relevant endpoints in obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM)Ticker(s): MYOK
Institution: The Permanente Medical Group (TPMG)
- Invasive cardiologist a multi specialty group with 600 physicians.
- Group manages about 150-200 patients with Hypertrophic cardiomyopathy.
- Familiar with the Mavacamten mechanism of action.
Please tell us about your clinical practice, background in treating Obstructive/Nonobstructive Hypertrophic/Dilated Cardiomyopathy, and research in the space. How many patients do you treat,what is the first line of therapy? What % of patients do not respond well to first line?Added By: c_admin
How much of a need for new treatments is still there? Which ones get prescribed often and under what specific circumstances?Added By: c_admin
Do you emphasize treating the underlying cause, or do you focus more on alleviating symptoms? How often does the enlarged myocardium regenerate to its normal size following medication?Added By: c_admin
What can you tell us about the recent P3 trial launch of mavacamten as an alternative to septal reduction therapy (SRT) ?Added By: c_admin
What are the risks/ benefits associated with surgical myectomy or alcohol septal ablation procedures?Added By: c_admin
What is Mavacamten’s mechanism of action leading to normalization of the number of myosin-actin cross-bridges?Added By: c_admin
How important is the allosteric control of beta cardiac myosin? Was it possible prior to the development of Mavacamten?Added By: c_admin
How likely would you be to switch your patients to Mavacamten if approved?Added By: c_admin
How important is the fact that mavacamten can be dosed to reduce left ventricular outflow tract (LVOT) gradient below the guideline-based definition for obstruction?Added By: c_admin
What are your views on using proBNP as an endpoint for noHCM? Are there other endpoints you think are more informative?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.